Competitive Rivalry

ResMed competes mainly with Philips and Fisher & Paykel in PAP and mask systems, but differentiated software and mask ecosystems support some pricing discipline.

The market remains concentrated enough that product quality, reimbursement access, and clinician preference matter, yet peer feature parity keeps rivalry from being structurally weak.

Recurring consumables and replacement cycles stabilize demand, but global peers still compete aggressively on mask refreshes and device upgrades, limiting margin expansion.

Philips’ post-recall disruption reduced near-term rivalry intensity, but normalized supply conditions should restore competitive pressure across global sleep-apnea peers.

Threat Of New Entrants

Regulatory approvals, clinical validation, and reimbursement pathways create meaningful barriers that make scale entry harder than in many medtech categories.

Established global distribution, installed-base relationships, and brand trust favor incumbents like ResMed and Philips over new entrants seeking hospital and home-care access.

Capital needs are manageable, but quality-system requirements and long product cycles raise the cost of credible entry relative to software-like healthcare niches.

New entrants can appear in niche accessories, yet they rarely match the breadth of device-plus-consumables economics enjoyed by global peers.

Bargaining Power Of Suppliers

ResMed sources electronics, plastics, and sensors from diversified suppliers, reducing dependence on any single input and limiting supplier leverage versus smaller peers.

Component standardization in many subassemblies weakens supplier pricing power, although specialized medical-grade parts can still create localized cost pressure.

Scale purchasing and multi-sourcing support better input terms than regional competitors, helping protect gross margin through procurement cycles.

Supplier power is more visible during semiconductor or logistics disruptions, but those shocks tend to affect the whole peer set rather than ResMed disproportionately.

Bargaining Power Of Buyers

Large payers, durable medical equipment channels, and hospital systems can negotiate aggressively, constraining realized pricing across global sleep-apnea peers.

Reimbursement-linked purchasing limits list-price flexibility, so margin outcomes depend more on mix and channel economics than on unilateral price increases.

End-user switching costs are moderate because masks and devices are clinically comparable, which keeps buyer leverage meaningful versus premium medtech franchises.

ResMed’s brand and installed base soften buyer pressure somewhat, but peers face similar reimbursement and procurement constraints, preventing a high score.

Threat Of Substitutes

Alternative therapies such as oral appliances, positional therapy, weight-loss interventions, and surgery cap long-run pricing power for PAP devices.

For moderate-to-severe obstructive sleep apnea, CPAP remains the standard therapy, so substitutes constrain growth more than they displace core economics.

Peer manufacturers face the same therapeutic alternatives, but ResMed’s recurring consumables model is still exposed if non-device treatments gain adoption.

Digital adherence tools can complement rather than replace PAP, so substitution pressure is real but not yet structurally dominant versus global peers.

Overall Score

ResMed benefits from high entry barriers and manageable supplier leverage, while rivalry, buyer power, and substitutes remain meaningful but not structurally overwhelming versus global peers.